London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for the response MoneyMunch. indeed very similar and well endorsed (Prostaphane) I'm taking it myself.
Will be interested to see what type of application JuveLife end up with.
It looks brilliant
15/6/20
INTELLECTUAL PROPERTY UPDATE
Our IP portfolio continues to be strengthened with a number of key patents being granted. The current status of the intellectual property portfolio is as follows:
-- From the "parent" patent family entitled "Stabilised Sulforaphane" patents are granted in Australia, Canada, EU, US, Japan and Hong Kong.
-- The principal manufacturing patent application, entitled "Methods of Synthesising Sulforaphane" is granted in Australia, China, Europe, Japan and further applications are pending in Brazil, Canada, US and India.
-- A second manufacturing patent which is directed to methods of isolating and purifying sulforaphane or analogues from natural sources has been granted in Europe, US, Japan and China.
-- The patent application providing protection around novel analogues based on sulforaphane, and entitled "Sulforaphane-Derived Compounds" is granted in Australia, China, Europe, Japan and the US and pending in Canada.
During the year composition of matter SFX-01 patents were granted both in Japan and Europe with a product claim for a complex of sulforaphane and alpha-cyclodextrin. The Group has long held broad compositional patent protection in the United States since patent grant in 2011 and in Canada since grant in 2014.
Furthermore, new composition of matter filings have been made which, if successful, would add a further 20 years of patent life to the key patent family.
Prostophane does sound similar to the nutrional health application using naturally derived sulforaphane recently licenced to Juvanescence.
However this is not the same thing as Evgen's SFX-1 product which is the foundation of all the potential clinical applications of sulforaphane.
Hi matadar, Prostaphane is obviously similar but is purely sold as a dietary supplement, and it would appear that SFX-01 is much more concentrated and so presumably much more potent. Gl ;-)
Detailed description of Prostaphane
Prostaphane® is the first and only dietary supplement based on active sulforaphane in free and stabilized form. Its patented formula has been the subject of clinical studies.
Function
Prostaphane® is intended for men age 45 or older, feeling the first signs of physiological aging of the prostate. Prostaphane® contributes to good prostate health, thanks to the antioxidant and anti-inflammatory qualities and cell-level protective action of its active sulforaphane content.
Composition
For one capsule: 10 mg of free, stabilized sulforaphane [CH3-SO-(CH2)4-NCS] from broccoli seeds.
Patented formula.
Ingredients: Maltodextrin, vegetal capsule (hydroxy propyl methylcellulose), broccoli seeds extract (Brassica Oleracea) titrated in sulforaphane, thickeners: acacia gum and magnesium stearate
........................
SFX-01
sulforaphane/alpha-cyclodextrin complex SFX-01
An orally available, stable powder formulation composed of sulforaphane, a naturally-occurring phytochemical belonging to the class of isothiocyanates, encapsulated within alpha-cyclodextrin, with chemopreventive activity. Upon administration of sulforaphane/alpha-cyclodextrin complex SFX-01, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2; NFE2L2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs mediate the transcription of various cytoprotective genes and antioxidant enzymes, particularly phase II detoxification enzymes, such as glutathione-S-transferase and quinone oxidoreductase, resulting in the detoxification of highly reactive carcinogens. Cyclodextrin is able to prevent sulforaphane's rapid breakdown, which improves its stability and half-life.
Evgen Pharma’s Sulforadex® technology unlocks the medical and commercial potential of sulforaphane (and related novel analogues) by synthesising a stable, solid form, active pharmaceutical ingredient. Lead product, SFX-01, is a patent-protected complex of sulforaphane and alpha-cyclodextrin in a stable powder.
Can anyone shed any light on how EVGENS technology for stabalization of Sulphurophane is different to the makers of Prostophane?
The French makers claim to have a similar technology.